Effects of Vaccination and Previous Infection on Omicron Infections in Children

Dan-Yu Lin et al.

On October 29, 2021, the Food and Drug Administration authorized the BNT162b2 vaccine (Pfizer–BioNTech) for emergency use in children 5 to 11 years of age, on the basis of an immunobridging study and a small efficacy study.1 Recent case–control studies have shown modest short-term effectiveness of the BNT162b2 vaccine in this age group during the early phase of the period when the B.1.1.529 (omicron) vari- ant of severe acute respiratory syndrome corona- virus 2 (SARS-CoV-2) was spreading (from mid- December 2021 to mid-February 2022).2-4 We conducted a large cohort study over a 6 month period when the omicron variant was dominant. Here, we report on the protection conferred by the BNT162b2 vaccine and by previous SARS- CoV-2 infection against infection and coronavirus disease 2019 (Covid-19)–related hospitalization and death in children 5 to 11 years of age.

Latest articles

Bruce Scott In Part I of Menticide 101 and the Brainwashing of...
Bruce Scott It has become quite clear, especially during the last two...
Joseph Mercola Scientists warn repeated COVID boosters may result in lowered immunity...
Mitchell Brent Liester Chlorine dioxide has been condemned as a dangerous poison...
Paul Elkins The recent White House guidance for people to take the...
Igor Chudov The times are changing! Remember how we said that vaccine shedding...

Your donation helps us
stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Thank you!

The form has been submitted successfully!